Back to Search Start Over

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications

Authors :
Jean-Luc Coll
Joel Plumas
Benoit Busser
Amandine Hurbin
Julie Charles
Laurence Chaperot
Patrice Faure
Marie Therese Leccia
Julien Lupo
Stéphane Mouret
Pierre Hainaut
Lucie Sancey
Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB)
Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Biochemistry Pharmacology and Toxicology Department
Centre Hospitalo-Universitaire de Grenoble
Laboratoire de Virologie [CHU Grenoble]
Centre Hospitalier Universitaire [Grenoble] (CHU)
Institut de biologie structurale (IBS - UMR 5075 )
Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA))
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)
Département de dermatologie, allergologie et photobiologie [Hôpital Michallon du CHU Grenoble Alpes]
Centre Hospitalier Universitaire [Grenoble] (CHU)-Hôpital Michallon
Hypoxie et physiopathologies cardiovasculaire et respiratoire
Institut National de la Santé et de la Recherche Médicale (INSERM)
Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)
Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2 )
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Thomas, Frank
Source :
BioMed Research International, BioMed Research International, Hindawi Publishing Corporation, 2017, 2017, pp.5986129. ⟨10.1155/2017/5986129⟩, BioMed Research International, 2017, 2017, pp.5986129. ⟨10.1155/2017/5986129⟩, BioMed Research International, Vol 2017 (2017)
Publication Year :
2017
Publisher :
HAL CCSD, 2017.

Abstract

Melanoma is a cutaneous cancer with an increasing worldwide prevalence and high mortality due to unresectable or metastatic stages. Mutations inBRAF,NRAS, orKITare present in more than 60% of melanoma cases, but a useful blood-based biomarker for the clinical monitoring of melanoma patients is still lacking. Thus, the analysis of circulating tumor cells (CTCs) and/or cell-free circulating tumor DNA (ctDNA) analysis from blood (liquid biopsies) appears to be a promising noninvasive, repeatable, and systemic sampling tool for detecting and monitoring melanoma. Here, we review the molecular biology-based strategies used for ctDNA quantification in melanoma patients, as well as their main clinical applications. Droplet digital PCR (ddPCR) and next generation sequencing (NGS) technologies appear to be two versatile and complementary strategies to study rare variant mutations for the detection and monitoring of melanoma progression. Among the different clinical uses of ctDNA, we highlight the assessment of molecular heterogeneity and the identification of genetic determinants for targeted therapy as well as the analysis of acquired resistance. Importantly, ctDNA quantification might also be a novel biomarker with a prognostic value for melanoma patients.

Details

Language :
English
ISSN :
23146133 and 23146141
Database :
OpenAIRE
Journal :
BioMed Research International, BioMed Research International, Hindawi Publishing Corporation, 2017, 2017, pp.5986129. ⟨10.1155/2017/5986129⟩, BioMed Research International, 2017, 2017, pp.5986129. ⟨10.1155/2017/5986129⟩, BioMed Research International, Vol 2017 (2017)
Accession number :
edsair.doi.dedup.....901c42c2a274bab209d77eb274776c93
Full Text :
https://doi.org/10.1155/2017/5986129⟩